NFL BIOSCIENCES Aktie

 

- Additional studies and analyses confirming the excellent safety profile of NFL-101, its immunological action associated with smoking abstinence, and its rapid and sustained effects on brain regions involved in addiction - Strengthening of the Scientific Advisory Board with world-renowned experts - Financing: €3 million capital increase in May 2025 and €1.2 million in non-dilutive funding obtained in July 2025, extending the cash runway until Q1 2027 - Scientific advice from European agencies and the U.S. FDA expected in the coming daysMONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces its half-year results for the period ended June 30, 2025, as approved by the Board of Directors on October 16, 2025, and provides an update on its clinical, industrial and financial developments. Bruno Lafont, Chief Executive Officer a...

A €600,000 “Innovation Advance” repayable advance granted by Bpifrance €600,000 in bank loans granted by Société Générale and Banque Populaire, the company's long-standing banking partners Additional non-dilutive funding expected as well as the Research Tax Credit reimbursement MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced that it has secured €1.2 million in medium-term non-dilutive financing from three partners. NFL Biosciences obtained a €600,000 “Innovation Advance” repayable advance from Bpifrance. This advance will be repaid interest-free over 5 years starting in the second quarter of 2029, in quarterly instalments of €30,000. The company has also secured two medium-term loans totalling €600,000 from its banking partners, repayable over 4 and 5 years at a fixed rate. This €1.2 million a...